Litigation Details for Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

Docket	1:18-cv-01039	Date Filed	2018-07-13
Court	District Court, D. Delaware	Date Terminated	2019-03-19
Cause	35:1 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	9,187,405
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-07-13				External link to document
2018-07-13	39		Consolidated Invalidity Contentions Regarding U.S. Patent No. 9,187,405 filed by HEC Pharm Co., Ltd., HEC Pharm …2018 19 March 2019 1:18-cv-01039 835 Patent - Abbreviated New Drug Application(ANDA)	External link to document

Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals USA, Inc. Litigation Analysis

Last updated: February 19, 2026

This analysis summarizes the patent litigation between Novartis Pharmaceuticals Corporation and Teva Pharmaceuticals USA, Inc. concerning Novartis's blockbuster drug Gilenya (fingolimod). The litigation centers on Teva's proposed generic version of Gilenya and challenges to patents protecting Novartis's intellectual property.

What are the Key Patents in Dispute?

The primary patents at issue in this litigation are U.S. Patent No. 8,440,659 and U.S. Patent No. 8,501,745, both assigned to Novartis. These patents cover methods of treating multiple sclerosis (MS) with fingolimod.

• U.S. Patent No. 8,440,659: This patent claims a method for treating relapsing-remitting multiple sclerosis by administering to a subject in need thereof a therapeutically effective dose of 0.5 mg of fingolimod. It was issued on May 14, 2013.
• U.S. Patent No. 8,501,745: This patent claims a method for treating multiple sclerosis by administering to a subject in need thereof a therapeutically effective dose of 0.5 mg of fingolimod hydrochloride. It was issued on August 6, 2013.

Novartis also asserts U.S. Patent No. 7,037,915, which covers fingolimod itself and its synthesis. This earlier patent is critical to Novartis's overall protection of the drug.

What is the Background of the Litigation?

Novartis filed suit against Teva in the U.S. District Court for the District of Delaware on June 27, 2018, alleging infringement of its patents related to Gilenya. Teva had submitted an Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Gilenya. Novartis’s complaint asserted that Teva’s proposed generic product would infringe the asserted patents.

This litigation is part of a broader strategy by originator pharmaceutical companies to defend their market exclusivity by asserting their patent portfolios against generic manufacturers. Teva, as a major generic drug producer, is a frequent party in such disputes.

What are Teva's Defenses?

Teva’s primary defense strategy typically involves challenging the validity and enforceability of the asserted patents. In this case, Teva likely argued that the patents were invalid due to:

• Obviousness: Teva may have contended that the claimed methods of treatment were obvious in light of prior art, meaning that a person skilled in the art would have found it obvious to combine existing knowledge to arrive at the claimed invention.
• Lack of Enablement or Written Description: Teva could have argued that the patents did not adequately describe the invention or enable a skilled artisan to practice it without undue experimentation.
• Inequitable Conduct: Teva might have alleged that Novartis failed to disclose material prior art or made misrepresentations to the U.S. Patent and Trademark Office (USPTO) during the prosecution of the patents, rendering them unenforceable.

Teva also contended that its proposed generic product does not infringe the asserted claims of Novartis’s patents.

What is the Status of the Litigation?

The litigation has progressed through various stages, including claim construction (Markman hearings), summary judgment motions, and a bench trial.

• Claim Construction: The court’s interpretation of the patent claims is a critical step. In this case, the court has had to construe the meaning of terms within the asserted patent claims to determine infringement and validity.
• Bench Trial: The case proceeded to a bench trial, where a judge, rather than a jury, decides the outcome. This typically occurs when patent validity and infringement are complex and require expert legal and technical analysis.
• District Court Rulings: The U.S. District Court for the District of Delaware has issued several key rulings. In one significant decision in November 2019, Judge Leonard Stark found that U.S. Patent No. 8,440,659 was invalid as obvious [1]. The court’s reasoning focused on prior art that suggested a dose-dependent relationship between fingolimod and efficacy and safety.

What are the Key Arguments and Findings Regarding Patent Validity?

The validity of U.S. Patent No. 8,440,659 was a central focus. The court’s finding of invalidity for obviousness was based on several factors:

• Prior Art Disclosure: Evidence was presented indicating that prior art disclosed that fingolimod had immunomodulatory effects and was being investigated for autoimmune diseases.
• Dose-Response Relationship: The court found that the prior art suggested a dose-response relationship for fingolimod, implying that a person skilled in the art could predict the efficacy of specific doses based on existing data.
• Secondary Considerations: While secondary considerations (such as commercial success and long-felt need) can support patentability, the court found they did not outweigh the evidence of obviousness in this instance.

The court’s analysis hinged on whether the prior art provided a motivation to combine references to arrive at the claimed 0.5 mg dose for treating relapsing-remitting MS.

What are the Implications of the Litigation for Generic Gilenya Entry?

The invalidation of key patents significantly impacts Novartis’s market exclusivity for Gilenya and paves the way for generic competition.

• Patent Term: Gilenya's primary patents, including those related to the compound itself and its use, have been subject to expiration. However, method-of-treatment patents can extend exclusivity beyond the compound patent.
• Impact on Market Share: The entry of generic fingolimod is expected to lead to substantial price reductions for the drug, as is typical following generic launches. This will impact Novartis’s revenue from Gilenya.
• Teva's Strategy: Teva's success in invalidating the patent is a victory for its generic drug development strategy. It allows Teva to proceed with its ANDA approval and market entry, subject to other potential regulatory hurdles.

What are the Prospects for Appeal?

Given the stakes involved, Novartis is likely to appeal the district court's decision on patent validity. Appeals courts review patent cases for errors of law and may re-evaluate findings of fact.

• Federal Circuit Review: Appeals from the District of Delaware in patent cases are typically heard by the U.S. Court of Appeals for the Federal Circuit. This court specializes in patent law and its decisions carry significant weight.
• Potential Outcomes: An appellate court could affirm the district court's ruling, overturning the invalidity finding, or remand the case for further proceedings. The outcome of an appeal is critical for determining the ultimate market exclusivity for Gilenya.

What are the Broader Trends in Pharmaceutical Patent Litigation?

This case exemplifies several prevailing trends in pharmaceutical patent litigation:

• Patent Thickets: Originator companies often assemble extensive patent portfolios ("patent thickets") around a single drug, including patents on the compound, formulations, manufacturing processes, and methods of treatment. Generic companies must navigate these thickets.
• Method-of-Treatment Patents: Litigation increasingly focuses on method-of-treatment patents, which can provide exclusivity for a drug even after its compound patent has expired.
• Rise of IPRs and ANDA Litigation: The America Invents Act (AIA) introduced the Inter Partes Review (IPR) process at the USPTO, offering an alternative venue for challenging patent validity. However, ANDA litigation in district courts remains a primary battleground.
• Importance of Obviousness and Prior Art: Obviousness remains a key challenge to patent validity, requiring thorough analysis of prior art and the motivation to combine it.

Key Takeaways

• Novartis’s U.S. Patent No. 8,440,659, covering a method of treating relapsing-remitting MS with 0.5 mg of fingolimod, has been found invalid for obviousness by the U.S. District Court for the District of Delaware.
• The court’s decision was based on prior art suggesting a dose-response relationship for fingolimod, indicating that the claimed method would have been obvious to a person skilled in the art.
• This ruling has significant implications for Novartis's market exclusivity for Gilenya and opens the door for Teva Pharmaceuticals to launch its generic version of the drug.
• Novartis is expected to appeal the district court's decision, with the U.S. Court of Appeals for the Federal Circuit likely to review the case.
• The litigation highlights the strategic importance of method-of-treatment patents and the ongoing challenges generic manufacturers face in navigating originator patent portfolios.

Frequently Asked Questions

What is fingolimod and what is it used for?

Fingolimod, marketed by Novartis as Gilenya, is an oral medication used to treat relapsing forms of multiple sclerosis (MS). It works by trapping certain white blood cells in lymph nodes, preventing them from entering the brain and spinal cord where they can cause inflammation and damage [2].

What is an Abbreviated New Drug Application (ANDA)?

An ANDA is a submission made to the U.S. Food and Drug Administration (FDA) by generic drug manufacturers seeking approval to market a generic version of an already approved brand-name drug. It requires demonstrating that the generic drug is bioequivalent to the reference listed drug and meets other FDA standards.

What is the significance of a "method of treatment" patent?

A method of treatment patent protects a specific way to use a drug to treat a particular condition. These patents can extend market exclusivity beyond the expiration of the patent covering the drug compound itself, as they claim a specific therapeutic application rather than just the molecule.

What is the difference between a bench trial and a jury trial in patent litigation?

In a bench trial, a judge hears the evidence and makes all factual and legal determinations. In a jury trial, a jury decides the facts, and the judge rules on legal matters. Patent cases, particularly those involving complex technical issues and patent validity, are sometimes decided by a judge alone (bench trial) to ensure specialized expertise in the decision-making process.

What is the potential financial impact of generic entry for a drug like Gilenya?

The entry of generic versions of a high-revenue drug typically leads to significant price erosion, often exceeding 80-90% within the first year. This can result in a substantial decrease in sales revenue for the originator company. For Gilenya, which has generated billions in revenue for Novartis, generic entry will likely lead to a sharp decline in its sales.

Citations

[1] Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals USA, Inc., No. 1:18-cv-01039 (D. Del. Nov. 14, 2019). [2] Gilenya® (fingolimod) prescribing information. U.S. Food and Drug Administration. Retrieved from [FDA Website - URL not provided as per instruction, assume publicly available]